T. Rowe Price Associates’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $132K | Buy |
35,328
+8,800
| +33% | +$32.9K | ﹤0.01% | 2835 |
|
|
2025
Q1 | $86K | Sell |
26,528
-18
| -0.1% | -$58 | ﹤0.01% | 2853 |
|
|
2024
Q4 | $148K | Sell |
26,546
-3,989
| -13% | -$22.2K | ﹤0.01% | 2761 |
|
|
2024
Q3 | $331K | Buy |
30,535
+491
| +2% | +$5.32K | ﹤0.01% | 2430 |
|
|
2024
Q2 | $631K | Buy |
30,044
+6,092
| +25% | +$128K | ﹤0.01% | 2097 |
|
|
2024
Q1 | $764K | Buy |
23,952
+1,356
| +6% | +$43.3K | ﹤0.01% | 2024 |
|
|
2023
Q4 | $458K | Buy |
22,596
+1,106
| +5% | +$22.4K | ﹤0.01% | 2212 |
|
|
2023
Q3 | $274K | Buy |
21,490
+2,570
| +14% | +$32.8K | ﹤0.01% | 2366 |
|
|
2023
Q2 | $342K | Buy |
18,920
+539
| +3% | +$9.74K | ﹤0.01% | 2303 |
|
|
2023
Q1 | $316K | Buy |
18,381
+1,002
| +6% | +$17.2K | ﹤0.01% | 2321 |
|
|
2022
Q4 | $386K | Sell |
17,379
-729
| -4% | -$16.2K | ﹤0.01% | 2266 |
|
|
2022
Q3 | $146K | Buy |
18,108
+2,318
| +15% | +$18.7K | ﹤0.01% | 2631 |
|
|
2022
Q2 | $110K | Buy |
15,790
+4,415
| +39% | +$30.8K | ﹤0.01% | 2731 |
|
|
2022
Q1 | $172K | Buy |
11,375
+700
| +7% | +$10.6K | ﹤0.01% | 2737 |
|
|
2021
Q4 | $234K | Buy |
+10,675
| New | +$234K | ﹤0.01% | 2697 |
|
|
2021
Q2 | – | Sell |
-279,746
| Closed | -$12.1M | – | 2925 |
|
|
2021
Q1 | $12.1M | Sell |
279,746
-63,932
| -19% | -$2.77M | ﹤0.01% | 1362 |
|
|
2020
Q4 | $14.2M | Buy |
+343,678
| New | +$14.2M | ﹤0.01% | 1295 |
|